Watch how liposomal doxorubicin is used after breast cancer
Part of Cancer, Skin clinical trials.
This is an observational study that follows people receiving add-on (adjuvant) chemotherapy after primary breast cancer. It aims to understand treatment patterns and outcomes for patients healthy enough to receive liposomal doxorubicin and who have no major complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 75 years old
- You have been diagnosed with primary (original) breast cancer, confirmed by biopsy
- Your after-surgery chemotherapy plan includes liposomal doxorubicin
- Your heart pumping strength is good (ejection fraction at least 55%)
- You have adequate blood counts and organ function based on recent lab tests
- You can sign consent and agree to follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study tests an additional (adjuvant) treatment for breast cancer after surgery and standard follow-up care. It may help lower the chance the cancer comes back, but you must match specific tumor and body-chemistry requirements to join.
This trial tests whether a corticosteroid cream can prevent or reduce hand-foot skin reactions caused by liposomal doxorubicin (a type of chemotherapy) in breast cancer patients. If you are starting this chemo and are concerned about skin side effects, this study may offer a way to manage them.
This study compares an “albumin-bound” form of paclitaxel versus other taxane chemotherapy options after breast surgery. It’s for people with HER2-negative, higher-risk breast cancer to see which approach works better in real-world care.
This trial tests a two-week schedule of two chemotherapy drugs (vinorelbine and liposomal doxorubicin) for people with HER2-negative advanced breast cancer who have already tried certain other chemotherapies. The goal is to see if this combo works well and is safe.
This trial tests whether adding the antibiotic doxycycline to standard chemotherapy before surgery can better target breast cancer stem cells in people with ER-positive, HER2-negative breast cancer. The goal is to improve treatment response.
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.